Chimerix to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – CMRX
The recorded move for CMRX in the trading session of this news was +2.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that management will participate in two upcoming investor conferences:
- H.C. Wainwright 25th Annual Global Investment Conference in New York City. Mike Andriole, Chief Executive Officer, will present a corporate overview on September 12, 2023 at 9:00 a.m. ET. A live audio webcast of the presentation can be accessed here and on the Investor Relations section of Chimerix’s website at ir.chimerix.com where it will be archived for approximately 90 days.
- Baird 2023 Global Healthcare Conference on September 13, 2023 in New York City, where management will participate in 1x1 meetings.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
CONTACTS:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
